Arrowhead Pharmaceuticals FY Conference Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Focus**: RNA interference (RNAi) technology with a broad pipeline of drug candidates, particularly in cardiometabolic diseases and central nervous system (CNS) disorders [2][3] Key Highlights - **Pipeline**: Approximately 21-22 drug candidates currently in clinical studies, with a strong emphasis on cardiometabolic conditions, including obesity [2] - **CNS Platform**: Introduction of a new CNS platform allowing for subcutaneous injections to address CNS disorders, with the first candidate ARO-MAPT targeting Alzheimer's disease [3][4] Upcoming Milestones - **Phase 3 Programs**: Expected readouts in Q3 2026 for SHASTA-3 and SHASTA-4, focusing on plozasiran, a triglyceride-lowering drug for patients with severe hypertriglyceridemia (SHTG) [3][4] - **CNS Data**: Anticipated data readout for ARO-MAPT in late Q3 or early Q4 2026, focusing on tau protein knockdown [5] - **Obesity Programs**: Additional data from ARO-INHBE and ARO-IL27 programs expected later in 2026, with a focus on adipose tissue targeting [6] Product Launch and Market Strategy - **Waylivra Launch**: Approved for familial chylomicronemia syndrome (FCS) with 100 prescriptions in the first 10 weeks, indicating a faster-than-expected launch [7][9] - **Pricing Strategy**: Priced at $60,000 per year, justified by the potential to reduce acute pancreatitis events in high-risk patients [17][19] - **Value Proposition**: Emphasizes the drug's ability to significantly lower triglyceride levels (around 80% reduction) compared to competitors [10][14] Competitive Landscape - **Differentiation**: Waylivra shows superior efficacy with no reported hypersensitivity or thrombocytopenia compared to Ionis' olezarsen, which has a higher non-responder rate [14][15] - **Market Positioning**: Aiming to establish a strong foothold in the high-risk population with a compelling clinical profile [19][20] Clinical Data Expectations - **SHASTA-3 and SHASTA-4**: Anticipated triglyceride reductions in the high 60s to low 70s percentage range, with a focus on translating these reductions into lower acute pancreatitis rates [22][23] - **Safety Monitoring**: Utilizing modified Atlanta criteria for characterizing acute pancreatitis events in clinical trials [26] Future Directions - **Dimer Development**: Exploring the combination of GalNAc siRNAs for mixed hyperlipidemia, targeting both LDL and triglycerides [46][47] - **Expansion into Other Markets**: Potential future studies in non-alcoholic fatty liver disease (NAFLD) and metabolic-associated steatotic liver disease (MASH) [40][46] Financial Position and Collaborations - **Current Financial Health**: Strong position with no immediate need for new partnerships; focus on existing collaborations and internal development [57][59] - **Future Collaborations**: Limited appetite for new partnerships in the near term, with a focus on maximizing current assets [59] Conclusion Arrowhead Pharmaceuticals is poised for significant developments in 2026, with a robust pipeline and strategic focus on cardiometabolic diseases and CNS disorders. The company is leveraging its RNAi technology to address unmet medical needs while maintaining a competitive edge in the market through innovative pricing and product differentiation.

Group 1 - Biogen has reinvigorated its Immunology and Inflammation (I&I) efforts, indicating a strategic shift beyond its historical focus on neuroscience [1] - The company's expertise in neuro-immunology, particularly in the central nervous system (CNS), underpins its strategy in I&I and kidney areas [1] - Biogen has been involved in lupus research for over a decade, highlighting its long-term commitment to immunological pathways [2] Group 2 - The development of drugs targeting immunological pathways is aimed at supporting a diverse product portfolio [2]